COVID_19_VE_Trial_Marker_SAP_26_Apr_2021.pdf (1.96 MB)

USG COVID-19 Response Team / CoVPN Vaccine Efficacy Trial Immune Correlates Statistical Analysis Plan

Download (1.96 MB)
online resource
posted on 26.04.2021, 13:59 by USG COVID-19 Response Team / Coronavirus Prevention Network (CoVPN) Biostatistics Team, Peter B. Gilbert, Youyi Fong, David Benkeser, Jessica Andriesen, Bhavesh Borate, Marco Carone, Lindsay N. Carpp, Ivan Diaz, Michael P. Fay, Andrew Fiore-Gartland, Nima S. Hejazi, Ying Huang, Yunda Huang, Ollivier Hyrien, Holly E. Janes, Michal Juraska, Kendrick Li, Alex Luedtke, Martha Nason, April K. Randhawa, Lars van der Laan, Brian Williamson, Wenbo Zhang, Dean Follmann
This Statistical Analysis Plan (SAP) describes the statistical analysis of antibody markers measured at a key time point post last vaccination as correlates of risk and as various types of correlates of protection against primary and secondary endpoints in COVID-19 Prevention Network (CoVPN) COVID-19 vaccine efficacy (VE) trials.

Funding

National Institute of Allergy and Infectious Diseases (NIAID) UM1AI068635

National Institute of Allergy and Infectious Diseases (NIAID) R37AI054165

History

Licence

Exports